Impact of body mass index on clinical outcomes in intestinal Behçet's disease.

IF 2.4 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Korean Journal of Internal Medicine Pub Date : 2025-07-01 DOI:10.3904/kjim.2024.349

Daye Park, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon

{"title":"Impact of body mass index on clinical outcomes in intestinal Behçet's disease.","authors":"Daye Park, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon","doi":"10.3904/kjim.2024.349","DOIUrl":null,"url":null,"abstract":"Background/aims: The impact of body mass index (BMI) on the clinical outcomes of intestinal Behçet's disease (BD) remains unclear. This study assessed the association between BMI and disease progression.Methods: A retrospective analysis of 760 patients with intestinal BD was conducted. Patients were classified by BMI as underweight (< 18.5 kg/m2), normal (18.5-22.9), overweight (23.0-24.9), or obese (≥ 25.0). The association between BMI and clinical outcomes-biologics, surgery, hospitalization, and emergency visits-was examined.Results: Among 760 patients, 130 (17.1%) were underweight, 384 (50.5%) normal, 152 (20.0%) overweight, and 94 (12.4%) obese. Higher BMI linked to lower cumulative rates of biologics use (p trend = 0.002), surgery (p trend = 0.004), hospitalization (p trend = 0.004), and emergency visits (p trend = 0.008). Compared with the underweight group, the normal (HR 0.667, 95% CI 0.483-0.922, p = 0.014), overweight (HR 0.589, 95% CI 0.394-0.879, p = 0.010), and obese groups (HR 0.515, 95% CI 0.321-0.828, p = 0.006) had lower hospitalization risks. The overweight (HR 0.490, 95% CI 0.241-0.996, p = 0.049) and obese (HR 0.312, 95% CI 0.116-0.840, p = 0.021) groups were negatively associated with future biologics use. The normal (HR 0.705, 95% CI 0.480-1.036, p = 0.075) and obese (HR 0.510, 95% CI 0.272-0.953, p = 0.035) groups were negatively associated with future surgery in multivariable analysis.Conclusion: Lower BMI was linked to poorer clinical outcomes in intestinal BD, emphasizing the need to optimize nutritional status.","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":"40 4","pages":"606-615"},"PeriodicalIF":2.4000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257004/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Korean Journal of Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3904/kjim.2024.349","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aims: The impact of body mass index (BMI) on the clinical outcomes of intestinal Behçet's disease (BD) remains unclear. This study assessed the association between BMI and disease progression.

Methods: A retrospective analysis of 760 patients with intestinal BD was conducted. Patients were classified by BMI as underweight (< 18.5 kg/m2), normal (18.5-22.9), overweight (23.0-24.9), or obese (≥ 25.0). The association between BMI and clinical outcomes-biologics, surgery, hospitalization, and emergency visits-was examined.

Results: Among 760 patients, 130 (17.1%) were underweight, 384 (50.5%) normal, 152 (20.0%) overweight, and 94 (12.4%) obese. Higher BMI linked to lower cumulative rates of biologics use (p trend = 0.002), surgery (p trend = 0.004), hospitalization (p trend = 0.004), and emergency visits (p trend = 0.008). Compared with the underweight group, the normal (HR 0.667, 95% CI 0.483-0.922, p = 0.014), overweight (HR 0.589, 95% CI 0.394-0.879, p = 0.010), and obese groups (HR 0.515, 95% CI 0.321-0.828, p = 0.006) had lower hospitalization risks. The overweight (HR 0.490, 95% CI 0.241-0.996, p = 0.049) and obese (HR 0.312, 95% CI 0.116-0.840, p = 0.021) groups were negatively associated with future biologics use. The normal (HR 0.705, 95% CI 0.480-1.036, p = 0.075) and obese (HR 0.510, 95% CI 0.272-0.953, p = 0.035) groups were negatively associated with future surgery in multivariable analysis.

Conclusion: Lower BMI was linked to poorer clinical outcomes in intestinal BD, emphasizing the need to optimize nutritional status.

查看原文本刊更多论文

体重指数对肠道behaperet病临床结局的影响

背景/目的：体重指数（BMI）对肠道behet病（BD）临床结局的影响尚不清楚。这项研究评估了BMI与疾病进展之间的关系。方法：对760例肠道BD患者进行回顾性分析。根据BMI将患者分为体重不足（< 18.5 kg/m2）、正常（18.5-22.9）、超重（23.0-24.9）和肥胖（≥25.0）。研究了BMI与临床结果（生物制剂、手术、住院和急诊）之间的关系。结果：760例患者中体重不足130例（17.1%），正常384例（50.5%），超重152例（20.0%），肥胖94例（12.4%）。较高的BMI与较低的生物制剂累计使用率（p趋势= 0.002）、手术（p趋势= 0.004）、住院（p趋势= 0.004）和急诊（p趋势= 0.008）相关。与体重过轻组相比，正常组（HR 0.667, 95% CI 0.483-0.922, p = 0.014）、超重组（HR 0.589, 95% CI 0.394-0.879, p = 0.010）和肥胖组（HR 0.515, 95% CI 0.321-0.828, p = 0.006）住院风险较低。超重组（HR 0.490, 95% CI 0.241-0.996, p = 0.049）和肥胖组（HR 0.312, 95% CI 0.116-0.840, p = 0.021）与未来使用生物制剂呈负相关。在多变量分析中，正常组（HR 0.705, 95% CI 0.480 ~ 1.036, p = 0.075）和肥胖组（HR 0.510, 95% CI 0.272 ~ 0.953, p = 0.035）与未来手术呈负相关。结论：较低的BMI与肠道BD的临床预后较差有关，强调了优化营养状况的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Korean Journal of Internal Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

5.10

自引率

4.20%

发文量

129

审稿时长

20 weeks

期刊介绍： The Korean Journal of Internal Medicine is an international medical journal published in English by the Korean Association of Internal Medicine. The Journal publishes peer-reviewed original articles, reviews, and editorials on all aspects of medicine, including clinical investigations and basic research. Both human and experimental animal studies are welcome, as are new findings on the epidemiology, pathogenesis, diagnosis, and treatment of diseases. Case reports will be published only in exceptional circumstances, when they illustrate a rare occurrence of clinical importance. Letters to the editor are encouraged for specific comments on published articles and general viewpoints.